Items Tagged ‘antibody-drug conjugate’

June 7th, 2016

First Targeted Therapy Shows Promise in Small Cell Lung Cancer


Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 […]

View full entry

Tags: antibody-drug conjugate, DLL3, Lung Cancer, Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Rova-T, Rovalpituzumab tesirine, sclc, small cell lung cancer, targeted therapy